Continuous Subcutaneous Lenalidomide Shows Promise in Reducing Toxicity in R/R Multiple Myeloma -...

Continuous Subcutaneous Lenalidomide Shows Promise in Reducing Toxicity in R/R Multiple Myeloma  Pharmacy Times

Tafasitamab Plus Lenalidomide and Rituximab Significantly Improves Outcomes in Relapsed/Refractor...

Tafasitamab Plus Lenalidomide and Rituximab Significantly Improves Outcomes in Relapsed/Refractory Follicular Lymphoma  The ASCO Post

Starton Therapeutics and Bend Bioscience Enter into - GlobeNewswire

Starton Therapeutics and Bend Bioscience Enter into  GlobeNewswire

Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA lon...

Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes | Leukemia  Nature

FDA Approves Tafasitamab Plus Lenalidomide and Rituximab for R/R Follicular Lymphoma - OncLive

FDA Approves Tafasitamab Plus Lenalidomide and Rituximab for R/R Follicular Lymphoma  OncLive

FDA Approves Monjuvi, Rituximab and Lenalidomide Combination for Relapsed or Refractory Follicula...

FDA Approves Monjuvi, Rituximab and Lenalidomide Combination for Relapsed or Refractory Follicular Lymphoma  Managed Healthcare Executive

Isatuximab May Represent New Standard of Care in Transplant-Ineligible Myeloma - Hematology Advisor

Isatuximab May Represent New Standard of Care in Transplant-Ineligible Myeloma  Hematology Advisor

Starton Therapeutics, Bend Partner to Advance STAR-LLD - Contract Pharma

Starton Therapeutics, Bend Partner to Advance STAR-LLD  Contract Pharma

Pfizer’s New Study on Elranatamab: A Potential Game-Changer in Multiple Myeloma Treatment - TipRanks

Pfizer’s New Study on Elranatamab: A Potential Game-Changer in Multiple Myeloma Treatment  TipRanks

Tafasitamab-Cxix With Rituximab, Lenalidomide Approved by FDA for Relapsed/Refractory Follicular ...

Tafasitamab-Cxix With Rituximab, Lenalidomide Approved by FDA for Relapsed/Refractory Follicular Lymphoma  Pharmacy Times

Dr Dimopoulos on Elranatamab Plus Daratumumab and Lenalidomide in Myeloma - OncLive

Dr Dimopoulos on Elranatamab Plus Daratumumab and Lenalidomide in Myeloma  OncLive

Acute lymphoblastic leukemia in patients treated with lenalidomide for multiple myeloma: a safety...

Acute lymphoblastic leukemia in patients treated with lenalidomide for multiple myeloma: a safety meta-analysis of randomized controlled trials combined with a retrospective study of the WHO’s pharmacovigilance database | Blood Cancer Journal  Nature

Lenalidomide Skin Rash May be Marker for Better Survival in Multiple Myeloma - Hematology Advisor

Lenalidomide Skin Rash May be Marker for Better Survival in Multiple Myeloma  Hematology Advisor

Dr Mehta on the FDA Approval of Tafasitamab Plus Rituximab/Lenalidomide in R/R Follicular Lymphom...

Dr Mehta on the FDA Approval of Tafasitamab Plus Rituximab/Lenalidomide in R/R Follicular Lymphoma  OncLive

Ixazomib or Lenalidomide combined with cyclophosphamide and dexamethasone in the treatment of eld...

Ixazomib or Lenalidomide combined with cyclophosphamide and dexamethasone in the treatment of elderly transplant-ineligible newly diagnosed multiple myeloma | Scientific Reports  Nature

Adding Daratumumab to Lenalidomide Maintenance Leads to Improved MRD in Newly Diagnosed MM - Hema...

Adding Daratumumab to Lenalidomide Maintenance Leads to Improved MRD in Newly Diagnosed MM  Hematology Advisor

Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transpla...

Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial  Nature

Cilta-Cel Emerges as a SOC in Lenalidomide-Refractory Multiple Myeloma - OncLive

Cilta-Cel Emerges as a SOC in Lenalidomide-Refractory Multiple Myeloma  OncLive

Addition of Daratumumab to Lenalidomide Maintenance Boosts MRD-Negative Conversions in Myeloma Fo...

Addition of Daratumumab to Lenalidomide Maintenance Boosts MRD-Negative Conversions in Myeloma Following ASCT  OncLive

Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgro...

Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study | Leukemia  Nature

Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma | Blood Cancer...

Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma | Blood Cancer Journal  Nature

Elranatamab Plus Daratumumab and Lenalidomide Is Active in Transplant-Ineligible Multiple Myeloma...

Elranatamab Plus Daratumumab and Lenalidomide Is Active in Transplant-Ineligible Multiple Myeloma  OncLive

Enterome presents positive Phase 2 interim results in - GlobeNewswire

Enterome presents positive Phase 2 interim results in  GlobeNewswire

Investigation of Glutarimide N -Alkylated Derivatives of Lenalidomide - ACS Publications

Investigation of Glutarimide N -Alkylated Derivatives of Lenalidomide  ACS Publications

Lenalidomide-induced pure red cell aplasia is associated with elevated expression of MHC-I molecu...

Lenalidomide-induced pure red cell aplasia is associated with elevated expression of MHC-I molecules on erythrocytes  Nature

Lenalidomide Drug Market to Reach USD 22.04 Bn by 2032 with A Growth Rate of 6.6% – Report by Coh...

Lenalidomide Drug Market to Reach USD 22.04 Bn by 2032 with A Growth Rate of 6.6% – Report by Coherent Market Insights  BioSpace

China’s NMPA Approves Tafasitamab Plus Lenalidomide in Transplant-Ineligible R/R DLBCL - OncLive

China’s NMPA Approves Tafasitamab Plus Lenalidomide in Transplant-Ineligible R/R DLBCL  OncLive

Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide - Business Wire

Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide  Business Wire

Lenalidomide/Dasatinib Receive FDA Approval in Hematologic Malignancies - CancerNetwork

Lenalidomide/Dasatinib Receive FDA Approval in Hematologic Malignancies  CancerNetwork

FDA Approves Generic Lenalidomide Capsules in Multiple Strengths - AJMC

FDA Approves Generic Lenalidomide Capsules in Multiple Strengths  AJMC

FDA Approves Brentuximab Vedotin Plus Lenalidomide/Rituximab for R/R LBCL - OncLive

FDA Approves Brentuximab Vedotin Plus Lenalidomide/Rituximab for R/R LBCL  OncLive

Lenalidomide combined with R-CHOP (R2-CHOP) in the treatment of newly diagnosed double-expressor ...

Lenalidomide combined with R-CHOP (R2-CHOP) in the treatment of newly diagnosed double-expressor diffuse large B-cell lymphoma: a prospective phase II clinical trial | Blood Cancer Journal  Nature

AACR 2025: Continuous Subcutaneous Lenalidomide Shows Promise in Reducing Toxicity in R/R Multipl...

AACR 2025: Continuous Subcutaneous Lenalidomide Shows Promise in Reducing Toxicity in R/R Multiple Myeloma  Pharmacy Times

Starton Therapeutics Announces Phase 2a Clinical Trial for Continuous Low-Dose Lenalidomide (STAR...

Starton Therapeutics Announces Phase 2a Clinical Trial for Continuous Low-Dose Lenalidomide (STAR-LLD) in Multiple Myeloma Open for Enrollment  Yahoo Finance

Cilta-Cel Provides Deep MRD Negativity in Lenalidomide-Refractory Multiple Myeloma - OncLive

Cilta-Cel Provides Deep MRD Negativity in Lenalidomide-Refractory Multiple Myeloma  OncLive

Dr Falchi on the Safety of Fixed-Duration Epcoritamab Plus Lenalidomide/Rituximab in R/R Follicul...

Dr Falchi on the Safety of Fixed-Duration Epcoritamab Plus Lenalidomide/Rituximab in R/R Follicular Lymphoma  OncLive

Impact of lenalidomide-bortezomib-dexamethasone induction on patients with newly diagnosed multip...

Impact of lenalidomide-bortezomib-dexamethasone induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect® MM Registry | Blood Cancer Journal  Nature

sBLA Submission Planned for Epcoritamab/Rituximab/Lenalidomide in R/R FL - OncLive

sBLA Submission Planned for Epcoritamab/Rituximab/Lenalidomide in R/R FL  OncLive

Selinexor combined with bortezomib, lenalidomide, and dexamethasone for the treatment of newly di...

Selinexor combined with bortezomib, lenalidomide, and dexamethasone for the treatment of newly diagnosed multiple myeloma with extramedullary disease | Scientific Reports  Nature

MRD Negativity Is Sustained After Cessation of Lenalidomide Maintenance in Multiple Myeloma - Onc...

MRD Negativity Is Sustained After Cessation of Lenalidomide Maintenance in Multiple Myeloma  OncLive

Reposition of lenalidomide as a radiation protector based on LINCS gene expression signatures and...

Reposition of lenalidomide as a radiation protector based on LINCS gene expression signatures and its preclinical validation  Nature

HRQOL Improved With Cilta-Cel in Lenalidomide-Refractory Multiple Myeloma - CancerNetwork

HRQOL Improved With Cilta-Cel in Lenalidomide-Refractory Multiple Myeloma  CancerNetwork

D-VRd Plus Daratumumab/Lenalidomide Maintenance Yields Favorable PFS Outcomes in High-Risk Myelom...

D-VRd Plus Daratumumab/Lenalidomide Maintenance Yields Favorable PFS Outcomes in High-Risk Myeloma  OncLive

Tafasitamab Plus Lenalidomide/Rituximab Improves PFS in Relapsed/Refractory Follicular Lymphoma -...

Tafasitamab Plus Lenalidomide/Rituximab Improves PFS in Relapsed/Refractory Follicular Lymphoma  OncLive

Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineli...

Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial  The Lancet

Real-World Data Support Rituximab Plus Lenalidomide in NHL - AJMC

Real-World Data Support Rituximab Plus Lenalidomide in NHL  AJMC

Salvage Isatuximab Combo Elicits Efficacy in Lenalidomide-Relapsed Myeloma - CancerNetwork

Salvage Isatuximab Combo Elicits Efficacy in Lenalidomide-Relapsed Myeloma  CancerNetwork

Clinical Experience Using Tafasitamab Plus Lenalidomide in DLBCL - OncLive

Clinical Experience Using Tafasitamab Plus Lenalidomide in DLBCL  OncLive

Combination Elranatamab, Daratumumab, Lenalidomide Shows Promise, Yielding a High Response Rate i...

Combination Elranatamab, Daratumumab, Lenalidomide Shows Promise, Yielding a High Response Rate in Newly Diagnosed MM  ASCO Daily News

Dr Falchi on the Efficacy of Fixed-Duration Epcoritamab Plus Lenalidomide and Rituximab in R/R Fo...

Dr Falchi on the Efficacy of Fixed-Duration Epcoritamab Plus Lenalidomide and Rituximab in R/R Follicular Lymphoma  OncLive

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma - insights.citeli...

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma  insights.citeline.com

FDA Accepts Amneal’s Abbreviated New Drug Application for Lenalidomide Capsules - Docwire News

FDA Accepts Amneal’s Abbreviated New Drug Application for Lenalidomide Capsules  Docwire News

ADAR1 Gene and Response to Lenalidomide in Patients With Multiple Myeloma - The ASCO Post

ADAR1 Gene and Response to Lenalidomide in Patients With Multiple Myeloma  The ASCO Post

Real-world experience of tafasitamab and lenalidomide for the treatment of R/R DLBCL - Lymphoma Hub

Real-world experience of tafasitamab and lenalidomide for the treatment of R/R DLBCL  Lymphoma Hub

Dr Garfall on Ide-Cel and Lenalidomide Maintenance in Myeloma After Suboptimal ASCT Response - On...

Dr Garfall on Ide-Cel and Lenalidomide Maintenance in Myeloma After Suboptimal ASCT Response  OncLive

Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible ...

Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-label, Multicenter, Randomized, Phase 3 Tr  OncLive

Luspatercept/Lenalidomide Combo Demonstrates Safety and Early Efficacy in Lower-Risk, Non-Del(5q)...

Luspatercept/Lenalidomide Combo Demonstrates Safety and Early Efficacy in Lower-Risk, Non-Del(5q) MDS  OncLive

Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with t...

Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients | Blood Cancer Journ  Nature

Elders With Lenalidomide-Refractory Myeloma May Lack Optimal Treatments - CancerNetwork

Elders With Lenalidomide-Refractory Myeloma May Lack Optimal Treatments  CancerNetwork

Cilta-Cel Significantly Boosts MRD Negativity Rates in Lenalidomide-Refractory Myeloma - OncLive

Cilta-Cel Significantly Boosts MRD Negativity Rates in Lenalidomide-Refractory Myeloma  OncLive

Cilta-Cel Achieves High MRD Negativity Rates in Lenalidomide-Refractory Multiple Myeloma - Cancer...

Cilta-Cel Achieves High MRD Negativity Rates in Lenalidomide-Refractory Multiple Myeloma  CancerNetwork

China’s NMPA Approves Tafasitamab/Lenalidomide in ASCT-Ineligible DLBCL - CancerNetwork

China’s NMPA Approves Tafasitamab/Lenalidomide in ASCT-Ineligible DLBCL  CancerNetwork

Future Directions After AURIGA: Daratumumab and Lenalidomide in Myeloma - Targeted Oncology

Future Directions After AURIGA: Daratumumab and Lenalidomide in Myeloma  Targeted Oncology

Addition of Brentuximab Vedotin to Lenalidomide Rituximab in Relapsed or Refractory DLBCL - The A...

Addition of Brentuximab Vedotin to Lenalidomide Rituximab in Relapsed or Refractory DLBCL  The ASCO Post

Brentuximab vedotin in combination with lenalidomide and rituximab receives U.S. FDA approval for...

Brentuximab vedotin in combination with lenalidomide and rituximab receives U.S. FDA approval for the treatment of R/R LBCL  Lymphoma Hub

Cilta-Cel Significantly Prolongs OS Vs SOC in Lenalidomide-Refractory Multiple Myeloma - OncLive

Cilta-Cel Significantly Prolongs OS Vs SOC in Lenalidomide-Refractory Multiple Myeloma  OncLive

ZR2 Plus R-DHAP and Zanubrutinib Maintenance With/Without ASCT Displays Promising Efficacy in New...

ZR2 Plus R-DHAP and Zanubrutinib Maintenance With/Without ASCT Displays Promising Efficacy in Newly Diagnosed MCL  OncLive

Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexam...

Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma  Nature

FDA Approves Brentuximab Vedotin, Lenalidomide, Rituximab Triplet for R/R LBCL - AJMC

FDA Approves Brentuximab Vedotin, Lenalidomide, Rituximab Triplet for R/R LBCL  AJMC

How effective is the combination of tafasitamab and lenalidomide in treating R/R DLBCL? - Lymphom...

How effective is the combination of tafasitamab and lenalidomide in treating R/R DLBCL?  Lymphoma Hub

“Icing and the Cherry on Top”: Cilta-Cel Improves Quality of Life in Multiple Myeloma - Oncology ...

“Icing and the Cherry on Top”: Cilta-Cel Improves Quality of Life in Multiple Myeloma  Oncology News Central

Tafasitamab in combination with lenalidomide approved by China’s National Medical Products Admini...

Tafasitamab in combination with lenalidomide approved by China’s National Medical Products Administration for adult patients with R/R DLBCL  Lymphoma Hub

Lenalidomide-Obinutuzumab Combo Yields Promising Results in Relapsed NHL - AJMC

Lenalidomide-Obinutuzumab Combo Yields Promising Results in Relapsed NHL  AJMC

Empliciti: Side effects, cost, dosage, and more - Medical News Today

Empliciti: Side effects, cost, dosage, and more  Medical News Today

Subcutaneous Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Therapy in Ne...

Subcutaneous Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Therapy in Newly Diagnosed Multiple Myeloma After Transplant: Primary Results from the Phase 3 AURIGA Study  OncLive

Dr Badros on the Efficacy of Daratumumab Plus Lenalidomide in Newly Diagnosed Myeloma - OncLive

Dr Badros on the Efficacy of Daratumumab Plus Lenalidomide in Newly Diagnosed Myeloma  OncLive

KarMMa-9 Study of Ide-Cel/Lenalidomide Maintenance in Newly Diagnosed Myeloma Discontinues Enroll...

KarMMa-9 Study of Ide-Cel/Lenalidomide Maintenance in Newly Diagnosed Myeloma Discontinues Enrollment  OncLive

Tafasitamab Plus Lenalidomide Wins Approval in Mexico for ASCT-Ineligible, R/R DLBCL - OncLive

Tafasitamab Plus Lenalidomide Wins Approval in Mexico for ASCT-Ineligible, R/R DLBCL  OncLive

Comparison of 6 cycles of isatuximab with lenalidomide, bortezomib and dexamethasone (I-VRd) vers...

Comparison of 6 cycles of isatuximab with lenalidomide, bortezomib and dexamethasone (I-VRd) versus 3 cycles of I-VRd followed by one cycle of high-dose melphalan in newly diagnosed low-risk multiple myeloma. Protocol for a multicenter, prospective, ran  Frontiers

Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving c...

Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4  Frontiers

Transfusion independence after lenalidomide discontinuation in patients with del(5q) myelodysplas...

Transfusion independence after lenalidomide discontinuation in patients with del(5q) myelodysplastic neoplasm: a HARMONY Alliance study | Leukemia  Nature

Isatuximab-Lenalidomide Demonstrates Strong Efficacy, Tolerability in Smoldering Multiple Myeloma...

Isatuximab-Lenalidomide Demonstrates Strong Efficacy, Tolerability in Smoldering Multiple Myeloma  Pharmacy Times

Tafasitamab With Lenalidomide Plus Rituximab Improves PFS in Patients With R/R FL - Pharmacy Times

Tafasitamab With Lenalidomide Plus Rituximab Improves PFS in Patients With R/R FL  Pharmacy Times

Daratumumab/Lenalidomide Improves MRD– Conversion Rates in Newly Diagnosed Myeloma After ASCT - O...

Daratumumab/Lenalidomide Improves MRD– Conversion Rates in Newly Diagnosed Myeloma After ASCT  OncLive

Cilta-Cel Improves MRD-Negativity Rates in Lenalidomide-Refractory Myeloma - OncLive

Cilta-Cel Improves MRD-Negativity Rates in Lenalidomide-Refractory Myeloma  OncLive

Dr Delforge on the Efficacy of Cilta-Cel in Lenalidomide-Refractory Myeloma - OncLive

Dr Delforge on the Efficacy of Cilta-Cel in Lenalidomide-Refractory Myeloma  OncLive

Dr Amengual on the Efficacy of Tazemetostat Plus Lenalidomide/Rituximab in Follicular Lymphoma - ...

Dr Amengual on the Efficacy of Tazemetostat Plus Lenalidomide/Rituximab in Follicular Lymphoma  OncLive

Dr Querfeld on Durvalumab Plus Lenalidomide vs Durvalumab in Advanced Cutaneous T-Cell Lymphoma -...

Dr Querfeld on Durvalumab Plus Lenalidomide vs Durvalumab in Advanced Cutaneous T-Cell Lymphoma  OncLive

Health Canada Approves Cilta-Cel for Relapsed/Lenalidomide-Refractory Myeloma - OncLive

Health Canada Approves Cilta-Cel for Relapsed/Lenalidomide-Refractory Myeloma  OncLive

Darzalex Monotherapy OK'd for Smoldering Multiple Myeloma - Medscape

Darzalex Monotherapy OK'd for Smoldering Multiple Myeloma  Medscape

ECHELON-3 trial: Brentuximab vedotin plus lenalidomide and rituximab for patients with R/R DLBCL ...

ECHELON-3 trial: Brentuximab vedotin plus lenalidomide and rituximab for patients with R/R DLBCL  Lymphoma Hub

inMIND trial: Tafasitamab plus lenalidomide and rituximab for R/R FL - Lymphoma Hub

inMIND trial: Tafasitamab plus lenalidomide and rituximab for R/R FL  Lymphoma Hub

Safety and activity of lenalidomide in combination with obinutuzumab in patients with relapsed in...

Safety and activity of lenalidomide in combination with obinutuzumab in patients with relapsed indolent non-Hodgkin lymphoma: a single group, open-label, phase 1/2 trial  The Lancet

Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q)...

Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial  The Lancet

Cilta-cel Maintains Survival Benefit in Lenalidomide-Refractory Multiple Myeloma - OncLive

Cilta-cel Maintains Survival Benefit in Lenalidomide-Refractory Multiple Myeloma  OncLive

Saeed Discusses Long-Term Outcomes and Real-World Data for Tafasitamab/ Lenalidomide in R/R DLBCL...

Saeed Discusses Long-Term Outcomes and Real-World Data for Tafasitamab/ Lenalidomide in R/R DLBCL  Targeted Oncology

Ibrutinib Plus Lenalidomide and Rituximab Demonstrates Activity in R/R MCL - OncLive

Ibrutinib Plus Lenalidomide and Rituximab Demonstrates Activity in R/R MCL  OncLive

New breakthrough combats lenalidomide resistance in multiple myeloma - NUS - National University ...

New breakthrough combats lenalidomide resistance in multiple myeloma  NUS - National University of Singapore

Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone ...

Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance  ASCO Publications

Sanofi Sarclisa recommended for EU approval by CHMP for transplant-eligible newly diagnosed multi...

Sanofi Sarclisa recommended for EU approval by CHMP for transplant-eligible newly diagnosed multiple...  Medical Dialogues